10x Genomics (NASDAQ:TXG) versus BioLife Solutions (NASDAQ:BLFS) Critical Analysis

BioLife Solutions (NASDAQ:BLFS) and 10x Genomics (NASDAQ:TXG) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, dividends, institutional ownership, risk, valuation, earnings and analyst recommendations.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for BioLife Solutions and 10x Genomics, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioLife Solutions	1	8	1	1	2.18
10x Genomics	1	10	5	0	2.25

BioLife Solutions presently has a consensus target price of $31.38, indicating a potential downside of 15.43%. 10x Genomics has a consensus target price of $38.31, indicating a potential downside of 41.17%. Given BioLife Solutions’ higher probable upside, research analysts plainly believe BioLife Solutions is more favorable than 10x Genomics.

Insider & Institutional Ownership

93.2% of BioLife Solutions shares are held by institutional investors. Comparatively, 84.7% of 10x Genomics shares are held by institutional investors. 2.2% of BioLife Solutions shares are held by company insiders. Comparatively, 8.8% of 10x Genomics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Risk & Volatility

BioLife Solutions has a beta of 1.93, suggesting that its stock price is 93% more volatile than the S&P 500. Comparatively, 10x Genomics has a beta of 2.03, suggesting that its stock price is 103% more volatile than the S&P 500.

Profitability

This table compares BioLife Solutions and 10x Genomics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
BioLife Solutions	53.29%	2.70%	2.49%
10x Genomics	-12.18%	-9.33%	-7.30%

Earnings & Valuation

This table compares BioLife Solutions and 10x Genomics”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioLife Solutions	$96.21 million	18.84	-$4.59 million	$1.16	31.98
10x Genomics	$642.82 million	13.20	-$43.54 million	($0.59)	-110.37

BioLife Solutions has higher earnings, but lower revenue than 10x Genomics. 10x Genomics is trading at a lower price-to-earnings ratio than BioLife Solutions, indicating that it is currently the more affordable of the two stocks.

Summary

BioLife Solutions beats 10x Genomics on 10 of the 15 factors compared between the two stocks.

About BioLife Solutions

BioLife Solutions, Inc. develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor Freeze Media that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; bioproduction tools, such as human platelet lysates for cell expansion and CellSeal closed system vials that are used in CGT; and the ThawSTAR line that comprises of a family of automated thawing devices for frozen cell and gene therapies packaged in cryovials and cryobags. The company also provides cryogenic freezer technology for controlled rate freezing and cryogenic storage of biologic materials; ultra-low temperature mechanical freezers; evo shipping containers that are cloud-connected passive storage and transport containers for temperature-sensitive biologics and pharmaceuticals; liquid nitrogen laboratory freezers, cryogenic equipment, and accessories; and biological and pharmaceutical storage and transport services. It markets and sells its products directly, as well as through third party distributors. The company was incorporated in 1987 and is headquartered in Bothell, Washington.

About 10x Genomics

10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity and networks on a cell-by-cell basis; single cell gene expression flex; single cell immune profiling used to study the immune system; single cell Assay for Transposase Accessible Chromati (ATAC) solution to understand the epigenetic state; and single cell multiome ATAC + gene expression which enables simultaneous interrogation of both the RNA and chromatin accessibility, using ATAC in a single cell. The company also provides Visium platform which enables researchers to understand the spatial positions of biological analytes within tissues at high resolution; and Xenium platform for in situ analysis. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.